Cost-Effectiveness of a Polypill for Cardiovascular Disease Prevention in an Underserved Population
Authors' conclusion
Results of this economic evaluation suggest that polypill treatment could be a high value intervention for a low-income, majority Black population with limited access to health care services.
Study context
- Population
- Southern Community Cohort Study (SCCS) Polypill Trial-representative cohort (majority Black, low-income population) and trial-eligible non-Hispanic Black US adultssimulated trial-representative cohort
- Participants
- 100,000 participants
- Comparison
- Polypill vs usual care
- Outcome
- Direct health care costs (US dollar 2023) and QALYs, both discounted 3% annually, and incremental cost per QALY gained
- Follow-up
- 10 years
Methodological detailsdiscrete-event simulation model, health care sector perspective, 10-year time horizon, 1-way and probabilistic sensitivity analysis
- Discrete-event simulation model
- Health care sector perspective
- 10-year time horizon
- 1-way and probabilistic sensitivity analysis
Main finding
As reported in the abstract
Additional quality-adjusted life-years (QALYs) (mean)
1190 QALYs
95% UI 287–2159
at a cost of approximately $10 152 000
Incremental cost per QALY gained
$8560 per QALY gained
Polypill
- High value (<$50 000 per QALY gained) in proportion of simulations
- 99%
- High value when priced at or below, per year
- $559
- Cost saving when priced at or below, per year
- $443
Further findings
| Outcome | Incremental cost per QALY gained (per QALY gained) |
|---|---|
| Cost per QALY gained, trial-eligible non-Hispanic Black US adults (secondary analysis)n = 3 602 427; high value | $13 400 |
Original publication
Cost-Effectiveness of a Polypill for Cardiovascular Disease Prevention in an Underserved Population. JAMA Cardiol. Published 1 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →